Table 1 Study population and products used in the study [ n (%) or median (IQR)]
Group ( n) | L. salivarius WB21 | L. salivarius TI 2711 | Ovalgen® DC | Xylitol |
|---|---|---|---|---|
Item | (n = 17) | (n = 16) | (n = 13) | (n = 18) |
Age | 24.0 (23.0 to 25.0) | 24.0 (23.0 to 25.0) | 24.0 (23.0 to 25.0) | 24.5 (23.0 to 26.0) |
Female (%) | 9 (52.9) | 6 (37.5) | 4 (30.8) | 6 (33.3) |
Mutans streptococci level (%) | ||||
Class 0 | 10 (58.8) | 10 (62.5) | 2 (15.4) | 9 (50.0) |
Class 1 | 2 (11.8) | 2 (12.5) | 4 (30.8) | 5 (27.8) |
Class 2 | 3 (17.6) | 2 (12.5) | 3 (23.1) | 2 (11.1) |
Class 3 | 2 (11.8) | 2 (12.5) | 4 (30.8) | 2 (11.1) |
Lactobacilli level (%) | ||||
Class 0 | 5 (62.5) | 6 (75.0) | 4 (57.1) | 5 (71.4) |
Class 1 | 0 (0.0) | 1 (12.5)) | 1 (14.3) | 2 (28.6) |
Class 2 | 3 (37.5) | 1 (12.5) | 2 (28.6) | 0 (0.0) |
Class 3 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Salivary flow (mL per 3 min) | 4.8 (3.3 to 5.8) | 7.3 (5.8 to 8.8) | 6.5 (3.5 to 7.0) | 5.5 (3.6 to 7.0) |
Salivary pH | 7.7 (7.6 to 7.9) | 7.9 (7.7 to 7.9) | 7.7 (7.5 to 7.9) | 7.7 (7.6 to 8.0) |
Buffering capacity | 5.7 (5.2 to 6.1) | 6.1 (5.9 to 6.1) | 5.9 (5.2 to 6.2) | 5.9 (5.6 to 6.3) |
Product name (company) | Minna No Zendamakin WB21 Tablet (Wakamoto Pharmaceutical Co.) | Super Kurish (Frente International Co.) | Hakira (BeanStalk) | Xylitol tablets (not for sale) (Wakamoto Pharmaceutical Co.) |
Active ingredient (per tablet) | L. salivarius WB21: 6.7 × 108 CFU | L. salivarius TI 2711: 2.8 × 108 CFU | Ovalgen® DC | Xylitol: 280 mg |
Xylitol: 280 mg | Xylitol: 450 mg | Xylitol: 100 mg | ||
Flavor | Mint | Clean mint | Orange | Mint |